This can be particularly difficult for patients who have made considerable changes to their eating habits and lifestyle but are still living with severe obesity.

Needing further treatment does not mean that the patient or their original surgery has failed. Obesity is a chronic, complex disease, and its management may need to change over time.

The American Society for Metabolic and Bariatric Surgery (ASMBS) recognises that further treatment may be appropriate when patients experience insufficient weight loss or weight recurrence following bariatric surgery.

For some patients, revisional bariatric surgery may be an option. One procedure that may be considered in carefully selected cases is Single Anastomosis Duodeno-Ileal Bypass with Sleeve Gastrectomy (SADI-S).

However, revising a previous gastric bypass to SADI-S is a complex operation and is not suitable for everyone.

Why Might Someone Need Further Surgery After Gastric Bypass?

Gastric bypass works by changing the size of the stomach and the way food passes through the digestive system. It also influences gut hormones involved in appetite, fullness and blood glucose regulation.

While many patients maintain meaningful weight loss over the long term, some may require further treatment.

There are several reasons why revisional surgery might be discussed.

Insufficient Weight Loss

Some patients lose a considerable amount of weight following gastric bypass but remain within a BMI range associated with severe obesity.

For example, someone who started with a particularly high BMI may have achieved substantial weight loss but still have obesity-related health concerns.

In these circumstances, further treatment may be considered to help address the remaining clinical risks.

Significant Weight Regain

Some weight regain can occur in the years following gastric bypass.

Changes in appetite regulation, metabolism, eating patterns, medication and the anatomy of the original bypass may all contribute.

Weight regain does not automatically mean that another operation is needed. A careful assessment is important to understand what has changed and whether medical, nutritional or surgical treatment would be most appropriate.

As outlined in the ASMBS statement on treatment options after bariatric surgery, treatment may include medication, endoscopic procedures or revisional surgery, depending on the patient’s circumstances.

Ongoing Obesity-Related Health Conditions

Weight loss is not the only measure of success following bariatric surgery.

Some patients may continue to experience conditions such as:

• Type 2 diabetes
• High blood pressure
• Obstructive sleep apnoea
• Joint pain and reduced mobility
• Other complications associated with severe obesity

Where significant obesity remains alongside these conditions, further treatment may be considered as part of an overall plan to improve long-term health.

What Is SADI-S and How Is It Different From Gastric Bypass?

SADI-S is a bariatric and metabolic procedure that combines a sleeve-shaped stomach with a bypass of part of the small intestine.

It works through changes in food intake, nutrient absorption and the hormonal signals involved in appetite and metabolism.

SADI-S is generally considered a more malabsorptive procedure than a standard Roux-en-Y gastric bypass, although the effects depend on the individual anatomy and surgical technique.

When a patient has already undergone gastric bypass, the operation is considerably more complex than performing SADI-S as a first bariatric procedure.

The surgeon must carefully assess the existing stomach and intestinal anatomy before determining whether reconstruction to a SADI-S configuration is technically possible and clinically appropriate.

Who Might Be Considered for Gastric Bypass to SADI-S Revisional Surgery?

There is no single BMI or weight regain threshold that automatically makes someone suitable for this type of revision.

However, certain circumstances may lead an experienced bariatric surgeon to consider whether it is an appropriate option.

Patients With Persistent Severe Obesity

Patients who continue to have a high BMI despite meaningful weight loss after gastric bypass may be considered for further assessment.

This may be particularly relevant where the remaining excess weight continues to affect mobility, metabolic health or quality of life.

The decision is based on more than BMI alone. The patient’s overall health, previous weight loss, surgical history and likely benefits and risks must all be considered.

Patients With Significant Weight Regain

For patients who have regained a substantial amount of weight, the first step is to understand why.

This may involve reviewing the original operation, examining the current anatomy and assessing nutritional, behavioural and medical factors.

If significant obesity persists and other treatment approaches have not provided sufficient benefit, revisional surgery may be discussed.

Patients Who Are Medically and Nutritionally Suitable

Revisional surgery requires careful consideration of the patient’s nutritional health.

Gastric bypass already affects the absorption of certain nutrients. SADI-S can increase the risk of protein and micronutrient deficiencies, making nutritional assessment particularly important.

The ASMBS nutritional guidelines emphasise the importance of screening for nutritional deficiencies and maintaining appropriate supplementation and monitoring following bariatric surgery.

Patients need to be able to follow long-term dietary guidance, take prescribed supplements and attend regular follow-up appointments.

Existing deficiencies may need to be corrected before surgery can be considered.

Why Is Assessment Particularly Important Before Revisional Surgery?

Revisional bariatric surgery is generally more technically demanding than a first bariatric operation.

Scar tissue, altered anatomy and changes from the previous procedure can increase surgical complexity.

An international consensus on revisional bariatric surgery highlights the importance of careful patient selection, multidisciplinary assessment and appropriate investigations before further surgery.

Before recommending further surgery, the multidisciplinary team may arrange investigations such as an upper gastrointestinal endoscopy, imaging and blood tests.

The assessment will also consider:

• The type of gastric bypass originally performed
• Weight loss and weight regain history
• Current BMI and obesity-related health conditions
• Existing nutritional deficiencies
• Digestive symptoms and previous surgical complications
• The patient’s ability to maintain long-term follow-up

These findings help determine whether further surgery is appropriate and, if so, which procedure may offer the most suitable outcome.

What About Recovery and Long-Term Care?

Recovery following revisional surgery varies depending on the complexity of the operation and the patient’s overall health.

As with other bariatric procedures, patients follow a staged dietary progression after surgery. However, the nutritional requirements following SADI-S need particular attention.

Long-term care includes monitoring protein intake, vitamin and mineral levels, weight changes and general health.

At Blackrock WeightCare, we recognise the importance of continued support following surgery. You can read more about our approach to weight loss aftercare.

Considering Further Surgery After Gastric Bypass?

Having undergone gastric bypass does not necessarily mean that all surgical treatment options have been exhausted.

For patients who continue to live with severe obesity or have experienced significant weight regain, a specialist assessment can help establish whether further treatment may be beneficial.

At Blackrock WeightCare, Mr William Robb and our experienced multidisciplinary team assess patients considering revisional bariatric surgery, including complex cases where SADI-S may be an option.

Every patient’s circumstances are different, and any recommendation for further surgery follows a careful review of their previous operation, current health and long-term needs.

If you would like to discuss your options, contact Blackrock WeightCare on 01 255 2479 or send us an enquiry.

Your Health. We Care.

The post Gastric Bypass to SADI-S Who Might Be Suitable for Revisional Surgery? appeared first on Blackrock WeightCare.

It is understandable. Most people preparing for weight loss surgery are thinking about how much they will be able to eat, what foods they can have and how quickly they might lose weight. Drinking water does not tend to be high on the list of concerns.

Yet hydration is something we pay close attention to during recovery.

Having cared for bariatric patients for many years, I have seen that the difficulty is rarely that someone does not understand the importance of drinking. More often, they are simply adjusting to the fact that they cannot drink in the same way they did before.

The good news is that, with a few simple habits, it usually becomes much easier.

Why can something as simple as drinking suddenly feel different?

Following a gastric sleeve, gastric bypass or SADI-S, taking in a large amount of fluid quickly may no longer feel comfortable, particularly during the early stages of recovery.

Some patients also experience nausea or changes in appetite and thirst. Add in everything else you are learning about your postoperative diet, protein, medications and activity, and it is easy to fall behind with fluids without noticing.

Dehydration is something we take seriously in bariatric care. Research involving more than 250,000 patients undergoing sleeve gastrectomy or gastric bypass found that dehydration requiring treatment was associated with emergency department visits and hospital readmission. 

That does not mean hydration needs to become a source of worry. It means we want patients to understand it and establish good habits early.

Forget the large glass. Think little and often

Patients sometimes tell me, “I just can’t get through that much water.”

My advice is not to look at the whole day’s fluid requirement as one big task.

You are not trying to drink a large glass at once. Small amounts, taken regularly across the day, are generally much easier to manage.

Your bariatric team will advise you on your individual fluid requirements. International bariatric guidance commonly refers to approximately 64 fluid ounces, or around 1.9 litres, per day, although individual requirements and postoperative plans can vary.

A few practical habits can make a real difference:

• Start your fluids early rather than trying to catch up later in the day.
• Keep your drink somewhere visible and within reach.
• Use a bottle with a known volume if that helps you keep track.
• Sip regularly rather than taking large drinks.
• Follow the guidance from your bariatric team about suitable fluids at each stage of recovery.

If you find plain water difficult to tolerate, let your bariatric team or dietitian know. There may be suitable alternatives depending on where you are in your postoperative plan.

You will need to rethink drinking with meals too

For many people, having a drink beside their meal is something they have done all their lives.

Following bariatric surgery, that habit needs to change.

BOMSS guidance recommends avoiding drinking with meals and leaving approximately 30 minutes between eating and drinking.

Initially, patients can find this one of the more awkward adjustments.

I usually reassure them that it becomes much more natural with time. What feels like a schedule during the first few weeks eventually becomes part of your normal routine.

Your body will usually give you a few clues

You do not need to become obsessed with measuring every millilitre you drink.

Instead, learn to recognise the signs that your intake may be falling behind.

A dry mouth, increasing thirst, headache, dizziness, unusual tiredness and urine that becomes noticeably darker or less frequent can all be signs that you need to pay attention to your hydration.

Vomiting or diarrhoea can increase the risk because you are losing fluids while potentially struggling to replace them.

I would much rather a patient contact us early because they are unsure than wait until they are feeling significantly unwell.

When is it more than just a difficult day?

There is an important difference between having a day when you have not quite reached your fluid goal and being unable to drink adequately.

Repeated vomiting, difficulty keeping fluids down, increasing difficulty swallowing or a significant drop in fluid intake should be discussed with your bariatric team.

Some days will require a little more attention

Warm weather, exercise, fever, vomiting and diarrhoea can all increase fluid losses.

Travel can catch people out too.

You may be walking more, sitting on a flight, spending time somewhere warmer or simply be out of your usual routine. If you are travelling after bariatric surgery, think about hydration before you leave rather than waiting until you become thirsty.

Eventually, you stop having to think about it so much

This is perhaps the reassurance I would most like to give someone preparing for bariatric surgery.

The early weeks involve a lot of learning.

Eating feels different. Drinking feels different. Your body is changing and you are trying to remember advice about nutrition, medication, activity and recovery.

It can feel like a lot at first.

But the patients I care for generally find that these new habits become increasingly normal. You learn what works for you. You recognise when you have not had enough to drink. And taking regular fluids becomes something you do without having to plan every sip.

The aim is not to be perfect. It is to understand your new body, build sensible habits and know when to ask for help.

At Blackrock WeightCare, we see bariatric surgery as much more than the operation itself. Preparing patients for the changes that come afterwards, and being there when questions arise, is an important part of bariatric care.

If you are considering bariatric surgery and would like to learn more about the treatment and ongoing support available at Blackrock WeightCare, complete the enquiry form here, or call us on 01 255 2479.

Your Health. We Care.

The post Why Hydration Can Be Harder After Bariatric Surgery and How to Stay on Top of It appeared first on Blackrock WeightCare.

Some people who have struggled with their weight for years are experiencing meaningful weight loss with tirzepatide. Their appetite may be easier to manage. Blood sugar control can improve. Everyday activities may become easier.

Then comes a question we hear increasingly often:

Will I have to take Mounjaro for the rest of my life to keep the weight off?

There is no single answer that applies to everyone. What we do know is that obesity is a chronic disease and, for many people, stopping an effective treatment can allow the biological drivers of weight gain to return.

That does not necessarily mean everybody who starts Mounjaro will remain on exactly the same medication or dose for life. It does mean that stopping treatment deserves more thought than simply reaching a particular number on the scales.

What happens when Mounjaro is stopped?

Mounjaro contains tirzepatide. It works on hormonal pathways involved in appetite, food intake and blood glucose regulation.

These effects are present while the medication is being taken. Stopping the medication does not permanently reset the body’s systems for regulating appetite and weight.

We have good clinical evidence showing what this can mean.

In the SURMOUNT-4 trial, people with obesity or overweight received tirzepatide for 36 weeks and achieved an average weight reduction of 20.9%. Participants were then assigned either to continue tirzepatide or switch to placebo for another year.

Those who continued treatment lost further weight. Those who stopped tirzepatide and switched to placebo experienced substantial weight regain.

This is important because it tells us that Mounjaro should not necessarily be viewed in the same way as a short course of antibiotics that is finished once the immediate problem improves.

Obesity usually requires a longer-term approach.

Weight regain does not mean the treatment failed

This point deserves particular attention.

Someone may take Mounjaro, lose a significant amount of weight and then regain some of that weight after stopping.

It can be very easy to interpret this as having gone backwards.

Clinically, that is not necessarily what has happened.

The medication was treating a chronic condition. Once treatment was withdrawn, some of the biological processes involved in that condition became more active again.

We see similar evidence with semaglutide. In an extension of the STEP 1 trial, participants regained around two-thirds of their previous weight loss during the year after semaglutide was stopped.

The lesson from these studies is not that weight-loss medication does not work.

In many patients, it works very well.

The more important lesson is that maintaining the benefit may require ongoing treatment.

Does that mean Mounjaro is a lifelong medication?

Potentially, for some people.

But “lifelong” can be an unhelpful way to think about the decision when somebody is only beginning treatment.

Obesity care can change over time.

A person may respond very well to medication and remain on it long term under medical supervision. Another may need a change in dose or medication. Someone else may stop because of side effects, cost, pregnancy planning or a change in their health.

There are also people living with more severe obesity for whom medication is helpful but does not provide enough improvement in obesity-related health conditions.

The more useful question is therefore:

What is my long-term treatment plan if Mounjaro is working for me?

That conversation should ideally happen before stopping rather than after weight regain has already occurred.

What if you have reached the weight you wanted?

Reaching a healthier weight does not necessarily mean that the underlying tendency towards obesity has disappeared.

This can feel counterintuitive.

We are accustomed to thinking that treatment should finish when the desired result has been achieved. Chronic diseases often work differently.

Blood pressure medication is not usually stopped simply because a person’s blood pressure has improved while taking it. The improvement may be evidence that the treatment is doing its job.

Obesity treatment can require similar long-term thinking.

Current European guidance describes obesity as a chronic, relapsing disease requiring sustained and personalised care. Long-term management should consider not only weight, but also conditions such as type 2 diabetes, cardiovascular disease, sleep apnoea, joint problems and quality of life.

What if you want to stop because of the cost?

This is particularly relevant in Ireland.

Many people are paying privately for weight-loss medication. A monthly expense that feels manageable for six months can look quite different when considered over several years.

Cost is therefore a legitimate part of the treatment conversation.

Stopping solely because the medication has “done its job”, without discussing what happens next, can leave somebody without a plan for maintaining the health improvements they have achieved.

Speak to the clinician managing your treatment before stopping. Depending on your circumstances, the discussion may include continued medical treatment, an alternative medication, nutritional and lifestyle support, or assessment for other obesity treatments.

When is it worth having a conversation about bariatric surgery?

Mounjaro can be a very effective treatment for obesity, but continuing medication indefinitely may not be the right approach for everyone. Some people experience weight regain when treatment stops, while others may still be living with severe obesity or conditions such as type 2 diabetes, sleep apnoea or high blood pressure despite losing weight with medication.

At this point, it may be worth looking beyond the next prescription and considering what treatment could offer a more durable approach to obesity.

Bariatric surgery is one such option. Procedures including gastric sleeve, gastric bypass and SADI-S can achieve substantial, sustained weight loss and improvements in obesity-related health conditions. Surgery also requires long-term commitment, including changes to eating, nutritional supplementation where required and ongoing follow-up, so it is a decision that deserves proper consideration.

Taking Mounjaro does not prevent you from exploring bariatric surgery, and considering surgery does not mean that your previous treatment has failed. It may simply be the next conversation to have about managing obesity over the longer term.

At Blackrock WeightCare, Mr William Robb and the multidisciplinary bariatric team can assess your health, weight history and previous treatment and discuss whether bariatric surgery may be appropriate for you.

To arrange a consultation, call 01 255 2479 or complete the enquiry form here.

Your Health. We Care.

The post Do You Have to Stay on Mounjaro for Life to Keep the Weight Off? appeared first on Blackrock WeightCare.

Many patients considering weight loss surgery in Ireland focus, understandably, on what happens in the first year. The weight loss is rapid, the changes are visible, and the impact on energy and health is often transformative. But the question I always want patients to think about is a longer one: what does this look like in ten years?

https://blackrockweightcare.ie/weight-loss-surgery-dublinThe answer, based on decades of high-quality evidence, is one of the most compelling stories in modern medicine. Bariatric surgery is not just about weight. It is about adding years to your life, reducing your risk of cardiovascular disease, cancer, and diabetes, and sustaining those benefits for the long term — not for months, but for decades.

Here is what the evidence actually shows.

The Big Picture: What 20 Years of Data Tells Us

The most authoritative long-term evidence comes from the Swedish Obese Subjects (SOS) study — a landmark prospective study that enrolled over 4,000 patients with obesity from 1987 to 2001 and followed them for up to 20 years. It remains the most comprehensive long-term investigation of bariatric surgery ever conducted.

Evidence · New England Journal of Medicine, 2020 — SOS Study

The SOS study found that, over 20 years of follow-up, patients who had bariatric surgery had an adjusted median life expectancy approximately 3 years longer than matched controls receiving usual obesity care. The hazard ratio for overall mortality was 0.77 — a 23% reduction. Cardiovascular mortality was reduced by 30%. The 90-day postoperative mortality in the surgical group was 0.2%.

These are not small improvements. A 3-year gain in life expectancy from a single intervention is a result that rivals many of the most celebrated treatments in cardiovascular medicine. And unlike medication, the effect does not stop when you stop taking something – because there is nothing to stop taking.

Year by Year: What to Expect

Year 1 — Rapid Transformation

The first year typically sees the most dramatic change. Most patients experience their fastest rate of weight loss in months 1–12.

• Average total body weight loss of 25–35% in the first year depending on procedure
• Type 2 diabetes improves or resolves — often within weeks of surgery, before major weight loss
• Blood pressure, sleep apnoea and joint pain typically improve significantly
• Energy levels, mobility and quality of life improve substantially

Years 2–5 — Consolidation

Weight loss typically slows and stabilises after the first 12–18 months. Some degree of weight regain is normal and expected in most patients — this does not represent failure.

• SOS study: mean weight loss of 23% at 2 years, stabilising to approximately 17% at 10 years
• Comorbidity resolution sustained — diabetes remission maintained in the majority
• The SLEEVEPASS trial (JAMA Surgery, 2022) confirmed sustainable weight loss for both sleeve and bypass at 10 years
• Cardiovascular risk factors continue to improve relative to non-surgical controls

Years 5–10 — Long-Term Durability

The defining period for durability. This is where bariatric surgery’s advantage over medication becomes most stark — medically-managed weight loss almost universally returns without ongoing treatment. Surgically-achieved weight loss largely persists.

• A systematic review and meta-analysis (O’Brien et al., Obesity Surgery, 2019) covering 57 datasets found all major bariatric procedures associated with durable weight loss at 10+ years
• Greater than 50% excess weight loss maintained for all current procedures at 10 years in the meta-analysis
• Mortality benefit becomes clearly established — SOS data shows advantage emerging over 10–13 years of follow-up
• Reduced incidence of myocardial infarction (adjusted HR 0.71) and stroke (adjusted HR 0.66) vs controls

15 Years and Beyond

The most compelling long-term data. Very few medical interventions for chronic disease can show benefits at this timeframe.

• SOS study: mean weight change of −16% at 15 years and −18% at 20 years in surgical group; essentially 0% in controls
• Cancer incidence reduced by 42% in women in the surgical group in the SOS study (men: no statistically significant difference)
• Life expectancy benefit sustained across all follow-up periods studied
• Patients with diabetes who achieved remission showed further reduction in long-term mortality risk

What About Weight Regain?

This is a question I encourage every patient to raise — because it deserves an honest answer. Some degree of weight regain after bariatric surgery is common and well-documented. It does not mean the surgery has failed, and it does not erase the benefits.

The SOS study data shows that even accounting for partial weight regain over time, surgical patients maintained substantially greater weight loss than non-surgical controls at every time point measured — 2, 10, 15 and 20 years. The cardiovascular and mortality benefits persisted regardless of the degree of regain.

Where significant weight regain does occur, we now have additional tools — including GLP-1 medication used as an adjunct — to help patients get back on track. This is part of what makes a comprehensive aftercare programme so important.

Beyond Weight: The Broader Health Benefits

Framing bariatric surgery purely as a weight loss procedure understates what it does. The most profound effects are often on conditions that carry the greatest health risk:

SOS Study · Summary of Key Outcomes at 10–20 Years

Type 2 diabetes: 83% reduction in new diagnoses; significant remission in those already diagnosed. Myocardial infarction: adjusted HR 0.71 (29% reduction). Stroke: adjusted HR 0.66 (34% reduction). Cancer (women): adjusted HR 0.58 (42% reduction). Overall mortality: adjusted HR 0.71–0.77 across follow-up periods. These outcomes are from published, peer-reviewed data in the New England Journal of Medicine and Journal of Internal Medicine.

These are not surrogate markers. These are deaths prevented, heart attacks avoided, and cancers that did not develop. The surgery that patients often fear most turns out to be one of the most powerful protective interventions available to people living with severe obesity.

Your Health. We Care.

The post What Does Bariatric Surgery Look Like after 5, 10 and 15 Years? appeared first on Blackrock WeightCare.

It is the frustration of someone who has watched obesity move through their family for years.

A mother who developed type 2 diabetes in her forties.
A father who struggled with weight and heart disease.
Siblings who are now facing the same pattern.

When that history is there, weight gain does not feel random. It feels inherited.

And many patients quietly ask the same question.

If this is in my genes, what chance do I really have?

The Role of Genetics in Obesity

Obesity is not simply the result of eating too much or moving too little. Modern research is clear that body weight is strongly influenced by biology. In fact, genetic factors can account for a significant proportion of a person’s tendency to gain weight.

Certain inherited traits affect how the brain regulates hunger and fullness. Some people feel satisfied quickly after a meal. Others feel persistent hunger even when they have eaten adequately. Some individuals burn energy more efficiently. Others store energy more readily.

When obesity runs in families, it is often because these biological signals are shared.

This is why two people can follow similar diets and exercise routines, yet experience very different results. One may lose weight steadily. The other may struggle constantly, losing and regaining weight despite genuine effort.

It is not a character flaw. It is physiology.

Why Weight Regain Is So Common

For patients with hereditary obesity, the body often defends its weight very aggressively.

When weight is lost through calorie restriction alone, the brain responds by increasing hunger hormones and reducing metabolic rate. The body interprets weight loss as a threat. It works to restore what has been lost.

If you are genetically predisposed, that response can be stronger and longer lasting.

This is why so many people describe years of dieting followed by regain. Over time, the cycle becomes exhausting. Confidence drops. Shame creeps in. And yet the underlying biology has never truly been addressed.

The Link With Diabetes and Other Conditions

Genetic obesity rarely exists in isolation. It is frequently associated with:

• Type 2 diabete
• High blood pressure
• Sleep apnoea
• Fatty liver disease
• Cardiovascular risk

In Ireland, we are seeing younger patients developing metabolic disease earlier than previous generations. A strong family history of diabetes or heart disease should not be ignored.

Obesity is not simply about weight. It is about long-term health risk.

Where Do Medications Like Ozempic and Mounjaro Fit

Treatments such as Ozempic and Mounjaro have changed how we approach obesity management. These medications act on gut hormones that regulate appetite and blood sugar. For many patients, they reduce constant hunger and make portion control achievable for the first time.

For individuals with moderate obesity, particularly those with early type 2 diabetes, these treatments can be very effective. They can reduce weight, improve HbA1c, and lower cardiovascular risk.

But for patients with severe obesity — particularly BMI over 40 or over 35 with significant medical complications — medication alone may not provide enough metabolic change to reverse established disease.

That does not mean medication has failed. It simply means the severity of the condition may require a more powerful intervention.

How Bariatric Surgery Addresses the Underlying Biology

Bariatric surgery, including gastric sleeve, gastric bypass and SADI-S, works at a deeper hormonal level.

It changes the communication between the gut and the brain. Hunger signals are reduced. Satiety improves. Insulin sensitivity increases. In many cases, blood sugar levels normalise rapidly after surgery, even before significant weight loss occurs.

For patients with hereditary obesity, this hormonal shift can counteract the biological drivers that have made weight control so difficult.

This is why bariatric surgery remains the most effective treatment for severe obesity and obesity-related type 2 diabetes. Long-term studies show sustained weight loss, high rates of diabetes remission and meaningful reductions in cardiovascular risk.

In Ireland and the UK, bariatric surgery is recognised as a medically necessary treatment for appropriate patients — not a cosmetic procedure.

Breaking a Pattern That Feels Inevitable

One of the most powerful moments in consultation is when a patient realises that their story does not have to follow the same path as their parents’.

If a parent required insulin in their fifties, that does not mean the same outcome is unavoidable.

If heart disease developed early in one generation, intervention can change the risk in the next.

Treating obesity effectively is not only about today. It is about reducing the likelihood of kidney disease, stroke, heart attack and mobility loss in the years ahead.

When obesity is genetic, early and appropriate treatment matters even more.

So Can Bariatric Surgery Help If Obesity Is Genetic

Yes. It can.

It does not erase your genes. But it can significantly reduce their impact.

For patients with severe or complex obesity, particularly those with a strong family history of metabolic disease, bariatric surgery offers the most durable improvement in weight, diabetes control and overall health risk.

The decision is never rushed. Assessment is careful. Medical treatment, including weight loss injections, may still have a role before or after surgery.

The goal is not simply weight reduction. The goal is long-term metabolic health.

You Are Not Alone In This

If obesity runs in your family and you feel that you have tried everything, it is important to understand that your experience is valid.

You may not lack discipline. You may be living with a chronic, genetically influenced disease that requires medical and possibly surgical care.

At Blackrock WeightCare, based at the Blackrock Clinic, we provide comprehensive obesity treatment including medical weight management and advanced bariatric surgery. Each patient is assessed individually, with careful consideration of family history, metabolic health and long-term goals.

If you would like to explore your options, you can begin by filling out a form on our website here or speak directly with our team on 01 255 2479.

Your Health. We Care.

The post Is Obesity Genetic, and Can Bariatric Surgery Help appeared first on Blackrock WeightCare.

If you are considering weight loss surgery in Ireland, one question comes up in almost every consultation: should I have the sleeve or the bypass?

It is the right question to ask. Both procedures are highly effective, both are proven to produce durable weight loss, and both are available at Blackrock WeightCare using Ireland’s first robotic bariatric surgery programme. But they work differently, suit different patients, and come with different long-term considerations.

There is no universal answer. But there is a best answer for you – and this guide will help you understand what that might be.

How Each Procedure Works

Gastric Sleeve (Sleeve Gastrectomy)

The stomach is permanently reduced to roughly 20% of its original size — forming a narrow, sleeve-shaped tube. This limits how much food you can eat and, critically, removes the portion of the stomach that produces most of the hunger hormone ghrelin. The result is that patients feel full faster and feel less hungry overall. There is no rerouting of the digestive system.

Gastric Bypass (Roux-en-Y Gastric Bypass)

A small stomach pouch is created at the top of the stomach, and the small intestine is rerouted to connect to it directly – bypassing the remainder of the stomach and the upper section of the small bowel. Food passes through a shorter digestive route. This produces powerful changes in gut hormones, and has particularly strong effects on conditions like type 2 diabetes, often producing remission before significant weight loss has even occurred.

How They Compare: The Evidence

Evidence · Lancet Diabetes & Endocrinology, 2025

The Oseberg trial — a long-term randomised controlled trial — found that gastric bypass was superior to sleeve gastrectomy for remission of type 2 diabetes at 5 years, with bypass patients more than twice as likely to achieve remission. Bypass also produced greater total weight loss and better outcomes for LDL cholesterol. The SleeveBypass trial (Lancet Regional Health, 2024) found the two procedures produced clinically comparable excess BMI loss at 5 years, though bypass showed advantages in total weight loss and cholesterol outcomes.

Who Is Each Procedure Best For?

Gastric Sleeve – Gastric Sleeve tends to suit patients who have no significant acid reflux, are looking for a technically simpler procedure, have a lower BMI range for surgery, do not have type 2 diabetes or have well-controlled diabetes, or wish to minimise the risk of nutritional complications.

Gastric Bypass – Gastric Bypass tends to suit patients who have type 2 diabetes or pre-diabetes, have significant acid reflux or GERD, have a higher BMI, have had a sleeve gastrectomy that produced insufficient weight loss, or where maximum metabolic benefit is the primary clinical goal.

It is important to be honest: these are guides, not rules. Individual anatomy, comorbidities, previous surgical history, and personal circumstances all factor into the recommendation. This is precisely why a thorough pre-operative assessment — including consultation with a dietitian, physician, and psychologist — is essential before any decision is made.

The landmark Swedish Obese Subjects (SOS) study — which followed over 4,000 patients for up to 20 years — found that bariatric surgery was associated with a 23% reduction in overall mortality compared to matched controls receiving usual care, and a 30% reduction in cardiovascular mortality. Surgery adds years to life. Both procedures share in this benefit.

A Note on Robotic Surgery

At Blackrock WeightCare, both sleeve gastrectomy and gastric bypass are available using Ireland’s first robotic bariatric surgery programme. Robotic-assisted surgery allows greater precision, improved visualisation, and can be particularly advantageous for patients with higher BMI or more complex anatomy. Mr Robb will advise at the consultation whether the robotic or laparoscopic technique is most appropriate for your procedure.

Your Health. We Care.

The post Gastric Sleeve vs Gastric Bypass: Which is Right for You? appeared first on Blackrock WeightCare.

The medical community’s understanding of obesity has undergone a significant evolution. Where it was once viewed primarily as a lifestyle issue — a comorbidity arising from poor choices — it is now increasingly classified as a chronic, progressive disease in its own right. This is not merely a semantic change. It has profound implications for how patients are assessed, counselled, and treated.

Obesity is now understood to be associated with more than 200 distinct health conditions. More significantly, it is no longer viewed as a consequence of those conditions — it is increasingly recognised as a driver of them. Adipose tissue, long dismissed as passive calorie storage, is now known to function as a highly active endocrine organ, secreting pro-inflammatory cytokines and metabolic mediators that exert systemic effects on the cardiovascular, hepatic, and renal systems.

“Obesity is not simply excess weight — it is a state of chronic biological dysfunction that reshapes the disease trajectory of multiple organ systems simultaneously.“

The Role of Visceral Adiposity

Not all fat is metabolically equivalent. At a healthy weight, the majority of adipose tissue is stored subcutaneously, where it functions as a relatively inert energy reserve. As fat mass increases, the body’s capacity for safe subcutaneous storage becomes overwhelmed, and lipid deposition shifts to visceral compartments — surrounding the liver, kidneys and heart.

Visceral adipose tissue is considerably more metabolically active than its subcutaneous counterpart. It exhibits higher lipolytic activity, generates excess free fatty acids, and produces pro-inflammatory mediators that enter the portal circulation directly. The downstream consequences — hepatic steatosis, insulin resistance, systemic inflammation, and accelerated cardiovascular risk — are well documented.

Genetic studies further suggest that individuals predisposed to visceral rather than subcutaneous fat storage carry a substantially elevated cardiometabolic risk profile, independent of total body weight.

Why Treatment Must Be Matched to the Individual

The emergence of GLP-1 receptor agonists has transformed the medical management of obesity, offering clinically meaningful weight reduction and cardiovascular benefit for many patients. However, the evidence is clear that these agents do not work uniformly. Approximately one in four patients with obesity does not achieve clinically significant weight loss with GLP-1 therapy alone — underscoring the heterogeneity of the condition and the need for a stratified treatment approach.

Bariatric surgery remains the most effective and durable intervention available for patients with severe obesity or those with significant metabolic comorbidities. Its benefits extend well beyond weight reduction: improvements in glycaemic control, blood pressure, hepatic steatosis, and cardiovascular risk are well established, and in many cases precede significant weight loss — suggesting mechanisms of action that go beyond caloric restriction alone.

The Diagnosis Gap — and Why Early Referral Matters

A further challenge is the persistent under-diagnosis of obesity in clinical practice. Recent data suggests that approximately 30% of individuals meeting the BMI threshold for obesity do not have a formal obesity diagnosis recorded. Earlier identification creates earlier opportunity — to intervene before comorbidities develop or compound, and to match patients to the treatment pathway most likely to be effective for their individual biology.

Blackrock WeightCare – Specialist Obesity Care in Dublin

Blackrock WeightCare provides comprehensive, evidence-based obesity treatment at the Blackrock Clinic. Our service offers bariatric surgical assessment and intervention, medical obesity management including GLP-1 therapies, and structured multidisciplinary follow-up – with a shared goal of delivering meaningful, sustained improvements in both weight and metabolic health.

For GPs considering referral, or for patients seeking specialist assessment, we welcome enquiries through our website. The right treatment, delivered at the right time, can change the long-term health trajectory of patients living with obesity.

Referring a patient or seeking a specialist consultation? We’d be glad to hear from you – 01 255 2479.

Your Health. We Care.

The post Obesity is a Disease of Biology, Not Behaviour – What the Latest Science Means for Treatment appeared first on Blackrock WeightCare.

If you have tried – really tried – to lose weight and found it almost impossible to keep off, there is something important you need to hear: your body is actively working against you. Not because you lack discipline. Not because you are not trying hard enough. But because of the way human biology is wired. 

New research is fundamentally changing how medicine understands obesity. Far from being a simple matter of eating less and moving more, obesity is now recognised as a chronic, systemic condition – one that involves the brain, the gut, the liver, the heart, and a remarkable organ most of us have never thought much about: fat tissue itself.

“Obesity is not a reflection of character. It is a biological condition – and like all biological conditions, it deserves proper medical treatment.”

Fat Tissue: The Hidden Organ Driving Your Health 

Most people think of body fat as inert – a passive store of excess calories. In reality, fat tissue is one of the most metabolically active organs in the body. It produces hormones, generates inflammatory signals, and communicates constantly with the brain and other organs. When fat accumulates in the wrong places – particularly around the abdominal organs – it stops functioning as a safe reservoir and starts actively disrupting the body’s normal processes.

This is why obesity is associated with so many seemingly unrelated health conditions: heart disease, type 2 diabetes, liver disease, joint problems, sleep apnoea, and even depression. It is not a coincidence – it is biology. The excess fat is driving inflammation and dysfunction throughout the body, often long before symptoms become obvious.

Why the Weight Comes Back

One of the most important and least talked about aspects of obesity is what happens when you lose weight. The body interprets any significant fat loss as a threat to survival. In response, it increases hunger hormones, reduces metabolic rate, and creates powerful cravings designed to bring your weight back up. This is not a lack of willpower. It is a deeply ingrained survival mechanism that has been shaped by millions of years of evolution.

This is also why short-term diets almost always fail in the long run, and why people often feel worse – more hungry, more obsessed with food – after losing weight than before. The body has shifted into defence mode.

There is No Single Solution – And That’s Why Expert Care Matters

Medical treatments for obesity have improved enormously in recent years. GLP-1 medications have helped many people achieve meaningful weight loss. But they don’t work for everyone – studies suggest up to a quarter of patients don’t achieve clinically significant results with medication alone. For others, bariatric surgery offers the most effective and durable long-term outcomes available.

The key is matching the right treatment to the right person – taking into account your individual biology, medical history, and goals. That is precisely what a specialist obesity service does.

Getting the Right Help in Dublin

At Blackrock WeightCare, based at the Blackrock Clinic, we take a comprehensive, evidence-based approach to obesity treatment. Whether your path involves medical management, bariatric surgery, or a combination of both, our team will work with you to build a treatment plan that fits your life – not a one-size-fits-all protocol.

If you have been struggling with your weight and feel you have run out of options, you have not. You may simply not yet have had access to the right support.

You can begin the conversation by visiting our contact page or speak directly with our team on 01 255 2479.

Your Health. We Care.

The post Why Losing Weight Is So Hard – And Why It’s Not About Willpower appeared first on Blackrock WeightCare.

Mr William Robb, Consultant Bariatric and Upper Gastrointestinal Surgeon at Blackrock WeightCare, has consistently emphasised that revision surgery should not be viewed as failure. Obesity is a chronic, relapsing disease. Surgical intervention is powerful, but long-term disease progression, anatomical factors and evolving metabolic challenges may require reassessment.

Understanding revision bariatric surgery

Revision bariatric surgery refers to a secondary procedure performed after a previous weight loss operation. This may involve:

• Conversion of one procedure to another
• Correction of anatomical complications
• Surgical management of inadequate weight loss or weight regain
• Treatment of severe reflux or nutritional complications

Revision surgery is technically more complex than primary bariatric surgery and should be undertaken in experienced, high-volume centres.

When should GPs consider referral?

There are several clear clinical scenarios where referral for specialist reassessment is appropriate.

1. Significant weight regain

Some degree of weight regain can occur several years after bariatric surgery and does not automatically indicate surgical failure. However, substantial regain — particularly when accompanied by recurrence of comorbidities such as type 2 diabetes, hypertension or obstructive sleep apnoea – warrants specialist review.

In clinical practice, revision referrals most commonly follow sleeve gastrectomy. While sleeve surgery is highly effective for many patients, a subset may experience weight regain over time or develop anatomical changes such as sleeve dilation. In selected cases, conversion to another metabolic procedure may restore weight control and improve metabolic outcomes.

GPs should consider referral when:

• BMI rises significantly above the patient’s post-operative low
• Glycaemic control deteriorates after a period of remission
• Antihypertensive or diabetic medication burden begins to increase again

Early referral allows structured reassessment, including dietary review, behavioural factors, metabolic evaluation and, where appropriate, imaging to assess anatomy.

2. Inadequate initial weight loss

A small proportion of patients may not achieve expected weight loss following primary surgery. This is again most frequently seen after sleeve gastrectomy, particularly in patients who began with higher BMI or severe metabolic disease.

In these cases, referral allows consideration of whether escalation to a more metabolically powerful procedure — such as gastric bypass or SADI-S — may be appropriate.

3. Persistent or severe reflux after sleeve gastrectomy

Gastro-oesophageal reflux disease is a recognised complication following sleeve surgery. Persistent reflux symptoms despite optimal medical therapy should prompt surgical evaluation.

Conversion from sleeve gastrectomy to gastric bypass is an established revisional strategy and can offer significant symptomatic relief in carefully selected patients.

Referral is appropriate when:

• Reflux remains uncontrolled despite proton pump inhibitors
• Endoscopic evidence of oesophagitis is present
• Barrett’s oesophagus develops or progresses

4. Complex or high BMI patients

Patients who began with BMI over 50, or those with severe metabolic disease, may occasionally require further intervention if initial weight loss has been insufficient.

Revisional bariatric surgery in these cases is technically complex and should be undertaken in experienced, high-volume centres with advanced minimally invasive or robotic capability.

Why experience matters in revision surgery

Revision bariatric surgery is inherently more complex than primary procedures. Previous surgery alters anatomy, creates adhesions and may change tissue planes. These factors require careful pre-operative planning and precise intraoperative technique.

Nutritional status, metabolic stability and psychological readiness must also be reassessed. Revision surgery is not simply a technical adjustment – it is a structured re-evaluation of a chronic disease pathway.

For this reason, revisional procedures are best undertaken in experienced, high-volume centres with advanced minimally invasive and robotic capability. Enhanced visualisation and instrument precision can be particularly valuable in complex cases where anatomy has already been modified.

Careful case selection, multidisciplinary discussion and structured follow-up remain central to safe and effective revision practice.

A collaborative approach with primary care

GPs play a pivotal role in long-term follow-up after bariatric surgery. Monitoring weight trajectory, glycaemic control, blood pressure and symptom progression allows early identification of patients who may benefit from reassessment.

Referral for revision surgery should not be interpreted as treatment failure. Obesity is a chronic metabolic condition. Disease progression, anatomical adaptation or evolving comorbidities may require adjustment of the original strategy.

At Blackrock WeightCare, referrals for revision assessment are welcomed via Healthlink. Each patient undergoes detailed review of previous operative history, current metabolic status, symptom profile and long-term goals before any recommendation is made.

The aim is always to restore metabolic control safely and appropriately.

Supporting your patients at the right time

GPs remain central to long-term care after bariatric surgery. When weight regain, relapse of diabetes or persistent reflux becomes apparent, early referral for reassessment can help prevent further progression.

Revision surgery is not about repeating the past, it is about adjusting the treatment pathway where needed.

At Blackrock WeightCare, every referral is reviewed carefully and individually. GPs can refer via Healthlink or contact the team directly to discuss a patient – 01 255 2479.

Your Health. We Care.

The post When should GPs consider referral for revision bariatric surgery appeared first on Blackrock WeightCare.

That’s the wrong question.

The right question is: what does this patient need, at this stage of their disease?

Obesity is chronic, progressive, and heterogeneous. The era of picking a lane — medical or surgical — is over. The best outcomes come from building integrated pathways. Here’s how I think we could think about it clinically.

BMI 27–35: Early intervention, metabolic protection

This is where the newer incretin therapies have genuinely expanded our toolkit. For patients without advanced complications, GLP-1s can achieve meaningful weight loss and delay progression to T2DM, NAFLD, and OSA. The goal here is prevention — getting in early before the disease accumulates damage. Medication earns its place at this stage, and I use it.

BMI 35–45: The judgment zone

No dogma here. This is where clinical decision making meets outcome data.

I’ll consider GLP-1s alone when diabetes is mild or very recently diagnosed and the patient is highly adherent. Endoscopic options when they want a lower-risk bridge with 15% total body weight loss (TBWL). Surgery when there’s severe GERD, significant visceral fat, liver fibrosis, established diabetes or a poor response to medical therapy.

Often the sequence is: surgery for the durability that drugs alone haven’t matched long-term. HbA1c, reflux burden, functional status, and what the patient can realistically sustain for 20 years, cumulative cost of injectables — these also can drive the decision for surgery versus a trial of medication, not the BMI alone.

BMI 45+: Surgery anchors the pathway

The data here hasn’t changed, and it won’t be overturned by a few years of GLP-1 trial data. For severe obesity with end-organ damage — fatty liver disease, refractory T2DM, sleep apnoea, joint destruction — metabolic surgery delivers weight loss and disease remission at a magnitude we cannot replicate pharmacologically with medications available to date. Not yet. Possibly not ever, for this cohort.

That said, GLP-1s have earned a genuine role around surgery: shrinking the liver pre-operatively in very high BMI patients, reducing anaesthetic risk, and rescuing for weight regain long after the operation. They can extend what surgery starts. They don’t replace what surgery does.

What the best programs are building

Stratify by more than BMI — we need to stratify patients by metabolic burden, genetics, psychological readiness, and social context all matter. Sequence therapies deliberately and consider what the correct combinations are based on the stage of the disease. Follow patients for decades, not months. And put surgeons, physicians, dietitians, and psychologists in the same room, sharing the same data.

The tribalism between “medical” and “surgical” camps has cost patients. The win here is designing systems that deliver the right option, to the right patient, at the right moment in their disease trajectory.

That’s precision obesity care. And it needs surgeons to build it.

Your Health. We Care.

The post Knife and Needles appeared first on Blackrock WeightCare.